# A Study to Evaluate the Safety, Tolerability and Efficacy of AK3280 Cream on Hypertrophic Scar

> **NCT05434897** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Shanghai Ark Biopharmaceutical Co., Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- Hypertrophic Scar

## Interventions

- **DRUG:** AK3280 Cream
- **DRUG:** Placebo cream

## Key facts

- **NCT ID:** NCT05434897
- **Lead sponsor:** Shanghai Ark Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07
- **Primary completion:** 2023-07
- **Final completion:** 2023-11
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05434897

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05434897, "A Study to Evaluate the Safety, Tolerability and Efficacy of AK3280 Cream on Hypertrophic Scar". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05434897. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*